M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV-1 Research

Executive Summary: M344 is a cell-permeable HDAC inhibitor with 100 nM potency, utilized for cancer and HIV-1 latency research (APExBIO). It induces gene expression changes through increased histone acetylation, leading to cell differentiation and apoptosis in several cancer cell lines (M344: Potent HDAC Inhibitor). M344 demonstrates GI50 values of 0.63–0.65 μM in MCF-7, D341 MED, and CH-LA 90 cells. It modulates transcription factors such as NF-κB and upregulates pro-apoptotic factors independently of p53. The compound is soluble in ethanol and DMSO, and its use requires precise handling and storage conditions for reproducible results. (M344: Unlocking the Power)

Biological Rationale

Histone deacetylase (HDAC) enzymes modulate chromatin structure by removing acetyl groups from lysine residues on histone tails, leading to condensed chromatin and transcriptional repression. Inhibition of HDACs results in increased histone acetylation, relaxed chromatin, and activation of gene expression. Aberrant HDAC activity is implicated in oncogenesis, including breast cancer, neuroblastoma, and medulloblastoma. HDAC inhibitors, such as M344, serve as targeted tools to induce cell differentiation, apoptosis, and growth arrest in cancer cells by altering epigenetic marks (Harnessing M344).

Mechanism of Action of M344

M344 directly binds to and inhibits HDAC enzymes with an IC50 of 100 nM. This binding is cell-permeable, allowing for effective intracellular modulation. HDAC inhibition by M344 leads to accumulation of acetylated histones. The resulting chromatin relaxation facilitates transcription of genes that promote cell cycle arrest, apoptosis, and differentiation. M344 upregulates pro-apoptotic factors such as Puma via p53-independent mechanisms, and modulates transcription factors including NF-κB, impacting pathways relevant to cancer and HIV-1 latency reversal (APExBIO M344).

Evidence & Benchmarks

• M344 exhibits an IC50 of 100 nM for HDAC inhibition in cell-based assays (APExBIO M344).
• In MCF-7 breast cancer cells, M344 displays a GI50 of 0.65 μM (cell viability inhibition, 72 h, standard medium) (APExBIO).
• M344 demonstrates similar GI50 values in medulloblastoma (D341 MED) and neuroblastoma (CH-LA 90) cell lines (~0.63 μM, 72 h) (APExBIO).
• Enhances radiosensitivity in human squamous carcinoma lines SCC-35 and SQ-20B (0.5–2 μM, pre-treatment for 24 h, followed by irradiation) (M344: Advanced HDAC Inhibitor).
• Induces pro-apoptotic factor Puma in a p53-independent manner (immunoblot, 24 h exposure, 1 μM) (M344: Unlocking the Power).
• Activates HIV-1 LTR gene expression, supporting anti-latency strategies in vitro (luciferase assay, 48 h, 1 μM) (Harnessing M344).
• Benchmarks confirm specificity for HDAC class I/II inhibition (HDAC activity assay, 100 nM–10 μM) (Redefining Epigenetic Modulation).

Applications, Limits & Misconceptions

M344 is utilized to study epigenetic regulation in preclinical models of cancer (breast, neuroblastoma, medulloblastoma) and in HIV-1 latency reversal. It is especially suited for apoptosis assays, cell cycle studies, and evaluating transcriptional reprogramming through histone acetylation modulation. As a research reagent, M344 is not approved for diagnostic or therapeutic use in humans. Its function in vivo is limited by pharmacokinetic properties and potential off-target effects at supra-physiological concentrations.

Common Pitfalls or Misconceptions

• M344 is not water soluble; improper solvent use may lead to precipitation and unreliable results (APExBIO).
• It is not intended for clinical or diagnostic applications; use is restricted to laboratory research (APExBIO).
• Long-term solution storage at room temperature or in aqueous buffer degrades compound potency (APExBIO).
• M344 cannot distinguish between HDAC isoforms in generic assays; isoform-selective approaches are needed for mechanistic studies.
• Assuming all cell lines will respond similarly is incorrect; sensitivity varies with genetic/epigenetic context (M344: Potent HDAC Inhibitor).

Workflow Integration & Parameters

M344 is supplied as a solid and shipped on blue ice. For use, dissolve in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL with ultrasonic treatment). Typical working concentrations in cell culture range from 1 to 100 μM, with treatment durations of 1–7 days. Stock solutions should be stored at −20°C, avoiding repeated freeze-thaw cycles. For optimal experimental reproducibility, prepare fresh working dilutions before each use. M344's robust cell permeability allows its use in multi-well plate formats and high-content screening. APExBIO provides detailed handling protocols for standardization (APExBIO).

This article extends M344: Potent HDAC Inhibitor by providing updated solvent compatibility and bench-use parameters, clarifies mechanistic nuances beyond M344: Unlocking the Power, and integrates new evidence on radiosensitization compared to M344: Advanced HDAC Inhibitor.

Conclusion & Outlook

M344, available from APExBIO (SKU: A4105), delivers potent HDAC inhibition with well-characterized efficacy in preclinical cancer and HIV-1 research. Its ability to induce histone acetylation, modulate key signaling pathways, and integrate into diverse cell-based workflows establishes it as a critical tool for epigenetic modulation studies. Ongoing work aims to refine its use in combination therapies and to elucidate isoform-selective effects, further expanding its translational relevance. For comprehensive experimental design, consult recent reviews and validated protocol resources (Cochrane Review).